Clinical Observation of Sodium-Glucose Cotransporter 2 Inhibitor in the Adjuvant Treatment of Acute Coronary Syndrome
Objective To investigate the clinical efficacy of sodium-glucose cotransporter 2(SGLT-2)inhibitors in the adjuvant treatment of acute coronary syndrome(ACS).Methods A total of 120 patients with ACS admitted to the Qinzhou First People's Hospital from August 2020 to August 2021 were selected and divided into the observation group and the control group according to the random number table method,with 60 cases in each group.The patients in the two groups received routine treatment,on this basis,the patients in the observation group received SGLT2 inhibitors such as empagliflozin or dapagliflozin.Both groups were continuously treated for 12 months.Results The total effective rate in the observation group was 91.67％,which was significantly higher than 78.33％in the control group(P<0.05).After one and six months of treatment,the cardiac function indexes[left ventricular end-diastolic volume(LVEDV)and left ventricular end-systolic volume(LVESV)]in the two groups significantly decreased(P<0.05),while the left ventricular ejection fraction(LVEF)in the two groups significantly increased(P<0.05),and the improvement of the above indexes in the observation group was significantly better than that in the control group(P<0.05).The levels of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)]in the two groups significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).The left ventricular remodeling indexes[soluble growth stimulation gene 2 protein(sST2),type Ⅰ procollagen carboxy-terminal peptide(PⅠCP),typeⅠ C-terminal collagen propeptide(CⅠTP)]in the observation group were significantly lower than those in the control group(P<0.05).After one month of treatment,the levels of myocardial enzyme profiles[lactate dehydrogenase(LDH),creatine kinase isozyme(CK-MB),creatine kinase(CK)]in the two groups significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).The incidence of major adverse cardiovascular events(MACE)in the observation group was 6.67％,which was significantly lower than 20.00％in the control group(P<0.05).Conclusion SGLT2 inhibitors are effective in the adjuvant treatment of ACS,which can effectively improve cardiac function,reduce myocardial injury and inflammatory reactions,reverse ventricular remodeling,and reduce the incidence of MACE.
万方数据
维普
